News

Sandoz Voluntarily Recalls All Lots of Methotrexate


 

Sandoz Inc. has voluntarily recalled all lots of Methotrexate Injection, after small glass flakes were found in four lots.

The glass flakes were found by Sandoz quality control, and are a result of delamination of the glass that is used to manufacture the vials, according to a statement released by Sandoz.

The manufacturer noted that lodging of the particles could lead to serious adverse events that could result in disability or death.

More information, including lot numbers, label type, and expiration date can be found on the Sandoz and Food and Drug Administration websites.

Patients should discontinue use of the product immediately.

Recommended Reading

RA Patients Require Thorough Heart Disease Screen
MDedge Internal Medicine
Doctors Don't Agree on How to Reform Medicare Payment
MDedge Internal Medicine
MRI Role in Knee Osteoarthritis Diagnosis Proposed by Expert Panel
MDedge Internal Medicine
High Tibial Osteotomy Use Dwindles as Total Knee Arthroplasties Rise
MDedge Internal Medicine
Markers of RA Severity, CV Markers Both Predict CV Events
MDedge Internal Medicine
Knee Rehab Deferred Cartilage Repair Surgery
MDedge Internal Medicine
Extending Zoledronic Acid Regimen Maintains Bone Density
MDedge Internal Medicine
Expert Panel Recommends "SubQ Switch" for Oral Methotrexate Nonresponders
MDedge Internal Medicine
Statin Use in RA Patients on Rituximab May Limit Treatment Effect
MDedge Internal Medicine
Patients Often Unaware of Infliximab Infusion Risk
MDedge Internal Medicine